Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Cintas Corporation (CTAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Cintas Corporation — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Cintas Corporation trades at $205.28 (market cap $81.25B). The key difference: Cintas Corporation is far larger — about 8.7× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Cintas Corporation pays a 1.02% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | CTAS | |
|---|---|---|
Market Cap | $9.39B | $81.25B |
Sector | Health | Industrials |
52-Week High | $356.25 | $225.10 |
52-Week Low | $241.71 | $163.55 |
Enterprise Value | $9.14B | $83.67B |
Dividend Yield | — | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
Cintas (CTAS) trades at $203.05, up 0.45% on the day, with a bullish technical signal and strong fundamental performance. The company reported Q2 2026 EPS of $1.29, beating estimates, and revenue growth continues with a 17.75% net income margin. Recent news highlights Bank of America's upgrade to 'Buy' and a quarterly dividend announcement, reflecting confidence in its outlook.
The outlook for CTAS is positive, supported by consistent earnings beats and robust profitability, though high valuation multiples like a P/E of 41.35 pose a risk. Upside exists toward the consensus price target of $225.83, but investors should monitor competitive pressures and economic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →
